FarHes

Hydroxyethyl starch.

FarHes Infusion: Each mL contains: Hydroxyethyl Starch (130/0.4) 60 mg.

Pharmacology: Hetastarch a colloidal volume substitute solution which is free from haemoprotein. HES is degraded continously by serum amylase and eliminated predominantly via the kidney.

In case of hypovolaemia a crystalloid solution should first be given. Hydroxyethyl starch (HES) is indicated for the treatment of hypovolaemia if patient does not responds to crystalloid solution.

Only for intravenous infusion. If not otherwise prescribed, according to blood loss and hematocrit up to approx 20 mL/kgbw/day equivalent to 1.2 g hydroxyethyl starch/kgbw/day=1500 mL in a 70 kg body weight patient.
In the case of septic shock due to burns, a lower administration rate of Farhes is necessary. Total calculations volume of colloidal volume substitution must be constant. Infusion rate: approximately 25 mL/kgbw/min and in adult 12.5-25 mL/min or 1000 mL in 40 to 80 min.

Do not use hydroxyethyl starch (HES) product in critically ill adult patients including patients with sepsis due to increased risk of mortality and renal replacement therapy.
Do not use HES product, in patients with severe liver disease.
Do not use HES products in patients with renal failure with oliguria or anuria not related to hypovolemia.
Do not use HES products in patients receiving dialysis treatment.

Avoid use in patients with pre existing renal dysfunction.
Discontinue use of HES product at the first sign of renal injury.
Continue to monitor renal function in hospitalized patients for at least 90 days as use of RRT has been reported up to 90 days after administrations of HES products.
In severe dehydration a crystalloid solution should be given first.
Monitor liver function in patients receiving HES products.
Monitor kidney function, fluid balance and serum electrolytes.

The product may lead to anaphylactoid reactions in isolated cases. In the event of intolerance reactions (see table) infusion is to be discontinued immediately and the standard emergency measures initiated: (See table.)


Click on icon to see table/diagram/image


Long-term, daily administration of FarHes infusion in medium and high doses frequently causes an almost untreatable itching. This can still occur weeks after ending the therapy, persist over months and could be strained for the patient. Only in a rare number of cases were pains in the kidney area reported. In such cases, infusion is to be continued immediately, sufficient fluid supplied and the serum creatinine values monitored closely. In higher doses, a prolongation of bleeding time can occur due to the dilution effect but clinically-relevant haemorrhage is not triggered. The fall in haematocrit and the dilution of the plasma proteins should be monitored.
Notes: The concentration of serum amylase can rise under administration of hydroxyethyl starch (interference with the diagnosis pancreatitis). A regular control of serum ionogramm and fluid balance is necessary.

No interactions with other drugs known to date.
Notes: Should mixing other drugs be necessary, 100% hygienic injection, through mixing, and above all, compatibility must be ensured.

Do not freeze. Store below 25°C.
Shelf-Life: 24 months

Intravenous & Other Sterile Solutions

B05AA07 - hydroxyethylstarch ; Belongs to the class of blood substitutes and plasma protein fractions. Used as blood substitutes.

G